180 related articles for article (PubMed ID: 15586282)
1. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer.
Sun H; Sloan A; Mangner TJ; Vaishampayan U; Muzik O; Collins JM; Douglas K; Shields AF
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):15-22. PubMed ID: 15586282
[TBL] [Abstract][Full Text] [Related]
2. Imaging DNA synthesis in vivo with 18F-FMAU and PET.
Sun H; Mangner TJ; Collins JM; Muzik O; Douglas K; Shields AF
J Nucl Med; 2005 Feb; 46(2):292-6. PubMed ID: 15695789
[TBL] [Abstract][Full Text] [Related]
3. Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET.
Tehrani OS; Muzik O; Heilbrun LK; Douglas KA; Lawhorn-Crews JM; Sun H; Mangner TJ; Shields AF
J Nucl Med; 2007 Sep; 48(9):1436-41. PubMed ID: 17785728
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats.
Bading JR; Shahinian AH; Vail A; Bathija P; Koszalka GW; Koda RT; Alauddin MM; Fissekis JD; Conti PS
Nucl Med Biol; 2004 May; 31(4):407-18. PubMed ID: 15093810
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract][Full Text] [Related]
6. Quantitative kinetics of [124I]FIAU in cat and man.
Jacobs A; Bräunlich I; Graf R; Lercher M; Sakaki T; Voges J; Hesselmann V; Brandau W; Wienhard K; Heiss WD
J Nucl Med; 2001 Mar; 42(3):467-75. PubMed ID: 11337525
[TBL] [Abstract][Full Text] [Related]
7. Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies.
Sun H; Collins JM; Mangner TJ; Muzik O; Shields AF
Cancer Chemother Pharmacol; 2006 Feb; 57(3):343-8. PubMed ID: 16001172
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT.
Nishii R; Volgin AY; Mawlawi O; Mukhopadhyay U; Pal A; Bornmann W; Gelovani JG; Alauddin MM
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):990-8. PubMed ID: 18057932
[TBL] [Abstract][Full Text] [Related]
9. Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents:
McHugh CI; Lawhorn-Crews JM; Modi D; Douglas KA; Jones SK; Mangner TJ; Collins JM; Shields AF
Cancer Imaging; 2016 Oct; 16(1):34. PubMed ID: 27751167
[TBL] [Abstract][Full Text] [Related]
10. Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Eiseman JL; Brown-Proctor C; Kinahan PE; Collins JM; Anderson LW; Joseph E; Hamburger DR; Pan SS; Mathis CA; Egorin MJ; Klecker RW
Clin Cancer Res; 2004 Oct; 10(19):6669-76. PubMed ID: 15475457
[TBL] [Abstract][Full Text] [Related]
11. In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET.
Conti PS; Bading JR; Mouton PP; Links JM; Alauddin MM; Fissekis JD; Ravert HT; Hilton J; Wong DF; Anderson JH
Nucl Med Biol; 2008 Jan; 35(1):131-41. PubMed ID: 18158952
[TBL] [Abstract][Full Text] [Related]
12. [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations.
Jadvar H; Yap LP; Park R; Li Z; Chen K; Hughes L; Kouhi A; Conti P
Mol Imaging; 2012; 11(5):426-32. PubMed ID: 22954187
[TBL] [Abstract][Full Text] [Related]
13. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2.
Tehrani OS; Douglas KA; Lawhorn-Crews JM; Shields AF
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1480-8. PubMed ID: 18265975
[TBL] [Abstract][Full Text] [Related]
14. Journey of 2'-deoxy-2'-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent.
Alauddin MM
Curr Med Chem; 2018; 25(16):1867-1878. PubMed ID: 29189119
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model.
Alauddin MM; Shahinian A; Gordon EM; Conti PS
Mol Imaging; 2004 Apr; 3(2):76-84. PubMed ID: 15296672
[TBL] [Abstract][Full Text] [Related]
16. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers.
Buursma AR; Rutgers V; Hospers GA; Mulder NH; Vaalburg W; de Vries EF
Nucl Med Commun; 2006 Jan; 27(1):25-30. PubMed ID: 16340720
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2'-Deoxy-2'-18F-Fluoro-beta-D-arabinofuranosyl)-5-iodouracil in normal dogs.
Nimmagadda S; Mangner TJ; Douglas KA; Muzik O; Shields AF
J Nucl Med; 2007 Apr; 48(4):655-60. PubMed ID: 17401105
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice.
Wang H; Oliver P; Nan L; Wang S; Wang Z; Rhie JK; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2002 May; 49(5):419-24. PubMed ID: 11976837
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of 2'-deoxy-2'-[18F]fluoro-5-bromo-1-beta-D-arabinofuranosyluracil ([18F]-FBAU) and 2'-deoxy-2'-[18F]fluoro-5-chloro-1-beta-D-arabinofuranosyl-uracil ([18F]-FCAU), and their biological evaluation as markers for gene expression.
Alauddin MM; Shahinian A; Park R; Tohme M; Fissekis JD; Conti PS
Nucl Med Biol; 2004 May; 31(4):399-405. PubMed ID: 15093809
[TBL] [Abstract][Full Text] [Related]
20. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers.
Lu L; Samuelsson L; Bergström M; Sato K; Fasth KJ; Långström B
J Nucl Med; 2002 Dec; 43(12):1688-98. PubMed ID: 12468521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
